Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
Glioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectio...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.845223/full |
| _version_ | 1819104766581538816 |
|---|---|
| author | Yuyang Liu Yuyang Liu Renqi Yao Renqi Yao Ying Shi Yuxiao Liu Hongyu Liu Jialin Liu Yunqian Guan Yongming Yao Ling Chen |
| author_facet | Yuyang Liu Yuyang Liu Renqi Yao Renqi Yao Ying Shi Yuxiao Liu Hongyu Liu Jialin Liu Yunqian Guan Yongming Yao Ling Chen |
| author_sort | Yuyang Liu |
| collection | DOAJ |
| description | Glioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectious and autoimmunity diseases. Nevertheless, the prognostic value of CD101 expression and its role in the immune microenvironment of various malignancies currently remains elusive. Herein, by adopting bioinformatics methodology, we comprehensively illustrated the potential function and predictive value of CD101 in stratifying clinical prognosis among patients with glioma, for which a high CD101 level predicted an unfavorable clinical outcome in glioma patients. Results from enrichment analyses manifested that CD101 predominantly expressed on the tumor-associated macrophages and was significantly associated with the immune regulatory processes, as evidenced by its positive correlation with immune-related genes and the putative infiltration of immune cells. Evidence provided by in-situ multicolor immunofluorescence staining further validated our findings at the protein level. Taken together, CD101 may serve as a novel biomarker in predicting clinical prognosis and immune status for glioma patients. |
| first_indexed | 2024-12-22T02:11:34Z |
| format | Article |
| id | doaj.art-b75d52875ae1424cb0f94c3ca723f6ae |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T02:11:34Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b75d52875ae1424cb0f94c3ca723f6ae2022-12-21T18:42:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-03-011310.3389/fimmu.2022.845223845223Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 MacrophagesYuyang Liu0Yuyang Liu1Renqi Yao2Renqi Yao3Ying Shi4Yuxiao Liu5Hongyu Liu6Jialin Liu7Yunqian Guan8Yongming Yao9Ling Chen10Medical School of Chinese People’s Liberation Army (PLA), Beijing, ChinaSenior Department of Neurosurgery, the First Medical Center of People’s Liberation Army (PLA) General Hospital, Beijing, ChinaTranslational Medicine Research Center, Medical Innovation Research Division and Fourth Medical Center of the Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaDepartment of Burn Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, ChinaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, ChinaSenior Department of Neurosurgery, the First Medical Center of People’s Liberation Army (PLA) General Hospital, Beijing, ChinaSenior Department of Neurosurgery, the First Medical Center of People’s Liberation Army (PLA) General Hospital, Beijing, ChinaSenior Department of Neurosurgery, the First Medical Center of People’s Liberation Army (PLA) General Hospital, Beijing, ChinaCell Therapy Center, Xuanwu Hospital, Capital Medical University, Beijing, ChinaTranslational Medicine Research Center, Medical Innovation Research Division and Fourth Medical Center of the Chinese People’s Liberation Army (PLA) General Hospital, Beijing, ChinaSenior Department of Neurosurgery, the First Medical Center of People’s Liberation Army (PLA) General Hospital, Beijing, ChinaGlioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectious and autoimmunity diseases. Nevertheless, the prognostic value of CD101 expression and its role in the immune microenvironment of various malignancies currently remains elusive. Herein, by adopting bioinformatics methodology, we comprehensively illustrated the potential function and predictive value of CD101 in stratifying clinical prognosis among patients with glioma, for which a high CD101 level predicted an unfavorable clinical outcome in glioma patients. Results from enrichment analyses manifested that CD101 predominantly expressed on the tumor-associated macrophages and was significantly associated with the immune regulatory processes, as evidenced by its positive correlation with immune-related genes and the putative infiltration of immune cells. Evidence provided by in-situ multicolor immunofluorescence staining further validated our findings at the protein level. Taken together, CD101 may serve as a novel biomarker in predicting clinical prognosis and immune status for glioma patients.https://www.frontiersin.org/articles/10.3389/fimmu.2022.845223/fullgliomamacrophageCD101immune infiltrationprognostic biomarker |
| spellingShingle | Yuyang Liu Yuyang Liu Renqi Yao Renqi Yao Ying Shi Yuxiao Liu Hongyu Liu Jialin Liu Yunqian Guan Yongming Yao Ling Chen Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages Frontiers in Immunology glioma macrophage CD101 immune infiltration prognostic biomarker |
| title | Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages |
| title_full | Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages |
| title_fullStr | Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages |
| title_full_unstemmed | Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages |
| title_short | Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages |
| title_sort | identification of cd101 in glioma a novel prognostic indicator expressed on m2 macrophages |
| topic | glioma macrophage CD101 immune infiltration prognostic biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.845223/full |
| work_keys_str_mv | AT yuyangliu identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT yuyangliu identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT renqiyao identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT renqiyao identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT yingshi identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT yuxiaoliu identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT hongyuliu identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT jialinliu identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT yunqianguan identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT yongmingyao identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages AT lingchen identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages |